Eunji Hwang
Research Subjects
Eunji Hwang has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
David Thwaites
Univ Sydney, Inst Med Phys, Sch Phys, Sydney, NSW, Australia
3 shared publicationsHien Le
Australian Bragg Centre for Proton Therapy and Research Adelaide South Australia Australia
3 shared publicationsPeter Gorayski
Australian Bragg Centre for Proton Therapy and Research Adelaide South Australia Australia
3 shared publicationsVerity Ahern
Western Sydney Local Hlth Dist, Radiat Oncol Network, POB 533, Wentworthville, NSW 2145, Australia
3 shared publicationsA.M. Crellin
NHS England National Clinical Lead Proton Beam Therapy, UK
2 shared publications- Adam Yeo
Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; RMIT University, School of Applied Sciences, Melbourne, Australia
2 shared publications
Latest Publications
- 17 December 2024
- Published by Elsevier in Clinical Oncology
- Vol. 38, 103739
Outcomes With Radiation Therapy as Primary Treatment for Unresectable Cutaneous Head and Neck Squamous Cell Carcinoma
- 17 December 2024
- Published by Elsevier in Clinical Oncology
- Vol. 38, 103739
Outcomes With Radiation Therapy as Primary Treatment for Unresectable Cutaneous Head and Neck Squamous Cell Carcinoma
- Open Access
Australian Particle Therapy Clinical Quality Registry (ASPIRE) protocol (TROG 21.12): a multicentre prospective study on patients with rare tumours, treated with radiation therapy
Introduction In 2020, the Australian Medical Services Advisory Committee (MSAC) recommended new proton beam therapy (PBT) item numbers be added to the Medicare Benefits Schedule. During the MSAC 1638 application process, MSAC recognised the uncertainties inherent in the cost-utility modelling of PBT. To address these uncertainties, MSAC proposed the establishment of a national registry with the intention to gather evidence to validate the claim of PBT’s superior toxicity outcomes and cost-effectiveness compared with conventional photon radiation therapy. Methods and analysis The Australian Particle Therapy Clinical Quality Registry is a prospective, observational, longitudinal registry collecting national data on paediatric, adolescent young adult and adult patients with rare tumours receiving any form of radiation therapy for a defined group of diseases, specified by the MSAC 1638 Public Summary Document. Eligible patients undergoing radiation therapy at participating institutions will be provided with information about the registry, including the opt-out procedure. The registry has no enrolment cap and will persist either indefinitely or until the conclusion of the study. The study design was informed by the Australian Metadata Online Repository and contains a core set of minimum data elements. Representing baseline participant demographics, assessment, diagnosis and treatment; incorporating radiation and systemic therapies, with a specific focus on long-term follow-up, treatment toxicities and specific organ-at-risk testing. Ethics and dissemination There will be no identifying data used in any reports or presentations of data. Additionally, all identifiable data will be safeguarded according to standard practices and available only to the host institution submitting the data to the registry. Aggregated data for the purposes of research will be stripped of identifiers. The registry has been approved under the National Mutual Agreement by the Central Adelaide Local Health Network Human Research Ethics Committee—HREC: 2021/HRE00394. Trial registration number Australian and New Zealand Clinical Trials Registry (ANZCTR): ACTRN12622000026729p.
Open AccessAustralian Particle Therapy Clinical Quality Registry (ASPIRE) protocol (TROG 21.12): a multicentre prospective study on patients with rare tumours, treated with radiation therapy
Introduction In 2020, the Australian Medical Services Advisory Committee (MSAC) recommended new proton beam therapy (PBT) item numbers be added to the Medicare Benefits Schedule. During the MSAC 1638 application process, MSAC recognised the uncertainties inherent in the cost-utility modelling of PBT. To address these uncertainties, MSAC proposed the establishment of a national registry with the intention to gather evidence to validate the claim of PBT’s superior toxicity outcomes and cost-effectiveness compared with conventional photon radiation therapy. Methods and analysis The Australian Particle Therapy Clinical Quality Registry is a prospective, observational, longitudinal registry collecting national data on paediatric, adolescent young adult and adult patients with rare tumours receiving any form of radiation therapy for a defined group of diseases, specified by the MSAC 1638 Public Summary Document. Eligible patients undergoing radiation therapy at participating institutions will be provided with information about the registry, including the opt-out procedure. The registry has no enrolment cap and will persist either indefinitely or until the conclusion of the study. The study design was informed by the Australian Metadata Online Repository and contains a core set of minimum data elements. Representing baseline participant demographics, assessment, diagnosis and treatment; incorporating radiation and systemic therapies, with a specific focus on long-term follow-up, treatment toxicities and specific organ-at-risk testing. Ethics and dissemination There will be no identifying data used in any reports or presentations of data. Additionally, all identifiable data will be safeguarded according to standard practices and available only to the host institution submitting the data to the registry. Aggregated data for the purposes of research will be stripped of identifiers. The registry has been approved under the National Mutual Agreement by the Central Adelaide Local Health Network Human Research Ethics Committee—HREC: 2021/HRE00394. Trial registration number Australian and New Zealand Clinical Trials Registry (ANZCTR): ACTRN12622000026729p.
- Open Access
- 28 October 2024
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 202, 110597
Identifying paediatric patients at risk of severe hearing impairment after treatment for malignancies of the H&N/CNS with proton therapy
- 28 October 2024
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 202, 110597
Open AccessIdentifying paediatric patients at risk of severe hearing impairment after treatment for malignancies of the H&N/CNS with proton therapy
- Open Access
- 16 February 2023
- Published by Elsevier in Clinical Oncology
- Vol. 35 (5) , 292-300
Outcomes of Patients Treated in the UK Proton Overseas Programme: Non-central Nervous System Group
- 16 February 2023
- Published by Elsevier in Clinical Oncology
- Vol. 35 (5) , 292-300
Open AccessOutcomes of Patients Treated in the UK Proton Overseas Programme: Non-central Nervous System Group
- Open Access
- 1 February 2023
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 67 (3) , 320-328
Proton‐to‐photon comparative treatment planning guidelines for the Australian context
Proton-to-photon comparative treatment planning is a current requirement of Australian Government funding for patients to receive proton beam therapy (PBT) overseas, and a future requirement for Medicare funding of PBT in Australia. Because of the fundamental differences in treatment plan creation and evaluation between PBT and conventional radiation therapy with x-rays (XRT), there is the potential for a lack of consistency in the process of comparing PBT and XRT treatment plans. This may have an impact on patient eligibility assessment for PBT. The objective of these guidelines is to provide a practical reference document for centres performing proton-to-photon comparative planning and thereby facilitate national uniformity.
- 1 February 2023
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 67 (3) , 320-328
Open AccessProton‐to‐photon comparative treatment planning guidelines for the Australian context
Proton-to-photon comparative treatment planning is a current requirement of Australian Government funding for patients to receive proton beam therapy (PBT) overseas, and a future requirement for Medicare funding of PBT in Australia. Because of the fundamental differences in treatment plan creation and evaluation between PBT and conventional radiation therapy with x-rays (XRT), there is the potential for a lack of consistency in the process of comparing PBT and XRT treatment plans. This may have an impact on patient eligibility assessment for PBT. The objective of these guidelines is to provide a practical reference document for centres performing proton-to-photon comparative planning and thereby facilitate national uniformity.
- 1 January 2022
- Published by Elsevier in Clinical Oncology
- Vol. 34 (1) , 11-18
A Novel Model and Infrastructure for Clinical Outcomes Data Collection and Their Systematic Evaluation for UK Patients Receiving Proton Beam Therapy
- 1 January 2022
- Published by Elsevier in Clinical Oncology
- Vol. 34 (1) , 11-18
A Novel Model and Infrastructure for Clinical Outcomes Data Collection and Their Systematic Evaluation for UK Patients Receiving Proton Beam Therapy
- 18 May 2020
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 64 (5) , 725-737
Particle therapy toxicity outcomes: A systematic review
Owing to its physical properties, particle therapy (PT), including proton beam therapy (PBT) and carbon ion therapy (CIT), can enhance the therapeutic ratio in radiation therapy. The major factor driving PT implementation is the reduction in exit and integral dose compared to photon plans, which is expected to translate to reduced toxicity and improved quality of life. This study extends the findings from a recent systematic review by the current authors which concentrated on tumour outcomes for PT, to now examine toxicity as a separate focus. Together, these reviews provide a comprehensive collation of the evidence relating to PT outcomes in clinical practice. Three major databases were searched by two independent researchers, and evidence quality was classified according to the National Health and Medical Research Council evidence hierarchy. One hundred and seventy‐nine studies were included. Most demonstrated acceptable and favourable toxicity results. Comparative evidence reported reduced morbidities and improvement in quality of life in head and neck, paediatrics, sarcomas, adult central nervous system, gastrointestinal, ocular and prostate cancers compared to photon radiotherapy. This suggestion for reduced morbidity must be counterbalanced by the overall low quality of evidence. A concerted effort in the design of appropriate comparative clinical trials is needed which takes into account integration of PT’s pace of technological advancements, including evolving delivery techniques, image guidance availability and sophistication of planning algorithms.
- 18 May 2020
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 64 (5) , 725-737
Particle therapy toxicity outcomes: A systematic review
Owing to its physical properties, particle therapy (PT), including proton beam therapy (PBT) and carbon ion therapy (CIT), can enhance the therapeutic ratio in radiation therapy. The major factor driving PT implementation is the reduction in exit and integral dose compared to photon plans, which is expected to translate to reduced toxicity and improved quality of life. This study extends the findings from a recent systematic review by the current authors which concentrated on tumour outcomes for PT, to now examine toxicity as a separate focus. Together, these reviews provide a comprehensive collation of the evidence relating to PT outcomes in clinical practice. Three major databases were searched by two independent researchers, and evidence quality was classified according to the National Health and Medical Research Council evidence hierarchy. One hundred and seventy‐nine studies were included. Most demonstrated acceptable and favourable toxicity results. Comparative evidence reported reduced morbidities and improvement in quality of life in head and neck, paediatrics, sarcomas, adult central nervous system, gastrointestinal, ocular and prostate cancers compared to photon radiotherapy. This suggestion for reduced morbidity must be counterbalanced by the overall low quality of evidence. A concerted effort in the design of appropriate comparative clinical trials is needed which takes into account integration of PT’s pace of technological advancements, including evolving delivery techniques, image guidance availability and sophistication of planning algorithms.
- 8 April 2020
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 64 (5) , 711-724
Particle therapy tumour outcomes: An updated systematic review
Summary: Particle therapy (PT) offers the potential for reduced normal tissue damage as well as escalation of target dose, thereby enhancing the therapeutic ratio in radiation therapy. Reflecting the building momentum of PT use worldwide, construction has recently commenced for The Australian Bragg Centre for Proton Therapy and Research in Adelaide – the first PT centre in Australia. This systematic review aims to update the clinical evidence base for PT, both proton beam and carbon ion therapy. The purpose is to inform clinical decision‐making for referral of patients to PT centres in Australia as they become operational and overseas in the interim. Three major databases were searched by two independent researchers, and evidence quality was classified according to the National Health and Medical Research Council evidence hierarchy. One hundred and thirty‐six studies were included, two‐thirds related to proton beam therapy alone. PT at the very least provides equivalent tumour outcomes compared to photon controls with the possibility of improved control in the case of carbon ion therapy. There is suggestion of reduced morbidities in a range of tumour sites, supporting the predictions from dosimetric modelling and the wide international acceptance of PT for specific indications based on this. Though promising, this needs to be counterbalanced by the overall low quality of evidence found, with 90% of studies of level IV (case series) evidence. Prospective comparative clinical trials, supplemented by database‐derived outcome information, preferably conducted within international and national networks, are strongly recommended as PT is introduced into Australasia.
- 8 April 2020
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 64 (5) , 711-724
Particle therapy tumour outcomes: An updated systematic review
Summary: Particle therapy (PT) offers the potential for reduced normal tissue damage as well as escalation of target dose, thereby enhancing the therapeutic ratio in radiation therapy. Reflecting the building momentum of PT use worldwide, construction has recently commenced for The Australian Bragg Centre for Proton Therapy and Research in Adelaide – the first PT centre in Australia. This systematic review aims to update the clinical evidence base for PT, both proton beam and carbon ion therapy. The purpose is to inform clinical decision‐making for referral of patients to PT centres in Australia as they become operational and overseas in the interim. Three major databases were searched by two independent researchers, and evidence quality was classified according to the National Health and Medical Research Council evidence hierarchy. One hundred and thirty‐six studies were included, two‐thirds related to proton beam therapy alone. PT at the very least provides equivalent tumour outcomes compared to photon controls with the possibility of improved control in the case of carbon ion therapy. There is suggestion of reduced morbidities in a range of tumour sites, supporting the predictions from dosimetric modelling and the wide international acceptance of PT for specific indications based on this. Though promising, this needs to be counterbalanced by the overall low quality of evidence found, with 90% of studies of level IV (case series) evidence. Prospective comparative clinical trials, supplemented by database‐derived outcome information, preferably conducted within international and national networks, are strongly recommended as PT is introduced into Australasia.
- 19 December 2017
- Published by Wiley in The Breast Journal
- Vol. 24 (4) , 615-619
Variations in breast cancer histology and treatment patterns between the major ethnic groups of South West Sydney
- 19 December 2017
- Published by Wiley in The Breast Journal
- Vol. 24 (4) , 615-619
Variations in breast cancer histology and treatment patterns between the major ethnic groups of South West Sydney
- Open Access
- 1 August 2017
- Published by Korean Academy of Pediatric Dentistry in THE JOURNAL OF THE KOREAN ACADEMY OF PEDTATRIC DENTISTRY
- Vol. 44 (3) , 358-364
An Evaluation of Shear Bond Strength of New Dentin Bonding Agents
- 1 August 2017
- Published by Korean Academy of Pediatric Dentistry in THE JOURNAL OF THE KOREAN ACADEMY OF PEDTATRIC DENTISTRY
- Vol. 44 (3) , 358-364
Open AccessAn Evaluation of Shear Bond Strength of New Dentin Bonding Agents